Castle Biosciences Named a Winner of the 2022 Top Workplaces USA Award

Award recognizes Castle’s commitment to a culture of transparency, teamwork and professional growth

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a leader in transforming disease management and improving patient outcomes through innovative diagnostics, today announced that it has received a 2022 Top Workplaces USA award from Energage. The Top Workplaces USA award celebrates organizations with 150 or more U.S. employees that have built exceptional workplace cultures. Recipients of the Top Workplaces USA award are chosen solely on employee feedback gathered through an employee engagement survey.

“From the beginning, we have strived to create something different at Castle – a place where we make decisions based on what is best for people: the patients who benefit from the information that our advanced diagnostic tests provide; the clinicians who use our tests to inform their disease management decisions; and our employees, the valued members of our Castle family,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “We are incredibly honored to have received the Top Workplaces USA award, and credit our fantastic employees, who embody our values of integrity, transparency, collaboration and innovation. At Castle, we understand that the true value of our company comes from our talented employees and believe that our focus on maintaining a positive culture helps us attract top talent, people who are willing to go the extra mile to make a difference in patient care.”

Castle has received numerous awards recognizing its strong company culture, innovation, leadership and overall company performance. Recent awards include: Inc.’s Best-Led Companies of 2021; the Houston Chronicle’s 2021 Top Workplaces; the Houston Chronicle’s “CHRON 100” list of the 100 most successful publicly traded companies in Houston in 2020 and 2021; a 2021 MedTech Breakthrough Award for the “Best New Technology Solution for Oncology” recognizing the Company’s DecisionDx®-SCC and DecisionDx® DiffDx™-Melanoma gene expression profile tests; a Healthcare Technology Report Top 100 Healthcare Technology Company in 2021; and a 2019 Technology Innovation in Melanoma Award from the American Skin Association.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company that provides personalized, clinically actionable information to clinicians and patients to inform treatment decisions and improve health outcomes. The Company is focused on transforming the disease management paradigm in skin cancer and other diseases with high clinical need by leveraging advanced technologies for its portfolio of innovative diagnostic tests.

Castle’s current portfolio consists of tests for skin cancers, uveal melanoma and Barrett’s esophagus. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq and TissueCypher are trademarks of Castle Biosciences, Inc.

About Energage

Making the world a better place to work together.^tm

Energage is a purpose-driven technology company that helps organizations build and brand Top Workplaces. Built on 14 years of culture research and the results from 23 million employees surveyed across more than 70,000 organizations, Energage delivers the most accurate competitive benchmark available. With access to a unique combination of patented analytic tools and expert guidance, Energage customers lead the competition with an engaged workforce and an opportunity to gain recognition for their people-first approach to culture. For more information or to nominate your organization, visit energage.com or topworkplaces.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. These forward-looking statements include, but are not limited to, statements concerning the ability of our portfolio of innovative diagnostic and prognostic tests to provide personalized, clinically actionable and life-changing information to clinicians and patients that improves disease management decisions for clinicians and health outcomes for patients. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the effects of the COVID-19 pandemic on our business and our efforts to address its impact on our business, subsequent study results and findings may contradict earlier study results and findings, including with respect to the diagnostic and prognostic tests discussed in this press release, actual application of our tests may not provide the aforementioned benefits to patients, and the risks set forth under the heading “Risk Factors” in our filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220202005171/en/

Investor Contact:

Camilla Zuckero

czuckero@castlebiosciences.com

Media Contact:

Allison Marshall

amarshall@castlebiosciences.com

Source: Castle Biosciences, Inc.